184.85
price down icon2.33%   -4.41
after-market Handel nachbörslich: 185.60 0.75 +0.41%
loading
Schlusskurs vom Vortag:
$189.26
Offen:
$189.62
24-Stunden-Volumen:
4.95M
Relative Volume:
0.73
Marktkapitalisierung:
$326.52B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
78.66
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
-3.48%
1M Leistung:
-0.24%
6M Leistung:
+7.09%
1J Leistung:
+7.27%
1-Tages-Spanne:
Value
$184.63
$189.90
1-Wochen-Bereich:
Value
$184.63
$192.34
52-Wochen-Spanne:
Value
$163.81
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Firmenname
Abbvie Inc
Name
Telefon
(847) 932-7900
Name
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Mitarbeiter
55,000
Name
Twitter
@abbvie
Name
Nächster Verdiensttermin
2025-04-25
Name
Neueste SEC-Einreichungen
Name
ABBV's Discussions on Twitter

Vergleichen Sie ABBV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-14 Herabstufung Citigroup Buy → Neutral
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-05 Herabstufung Daiwa Securities Outperform → Neutral
2024-11-22 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-04 Hochstufung Argus Hold → Buy
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-06-05 Hochstufung HSBC Securities Hold → Buy
2024-05-17 Eingeleitet Cantor Fitzgerald Overweight
2024-01-29 Hochstufung William Blair Mkt Perform → Outperform
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-12-11 Hochstufung Goldman Neutral → Buy
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-30 Hochstufung Barclays Equal Weight → Overweight
2023-10-20 Fortgesetzt UBS Neutral
2023-09-29 Eingeleitet Raymond James Outperform
2023-07-25 Eingeleitet William Blair Mkt Perform
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-05 Herabstufung Argus Buy → Hold
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-22 Herabstufung Wolfe Research Outperform → Peer Perform
2023-02-10 Hochstufung SVB Securities Underperform → Market Perform
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-11-08 Herabstufung Societe Generale Buy → Hold
2022-08-01 Herabstufung Atlantic Equities Overweight → Neutral
2022-05-23 Eingeleitet SVB Leerink Underperform
2022-05-06 Herabstufung Daiwa Securities Outperform → Neutral
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-02-28 Herabstufung UBS Buy → Neutral
2022-02-03 Bestätigt BMO Capital Markets Outperform
2022-02-03 Bestätigt Barclays Equal Weight
2022-02-03 Bestätigt BofA Securities Neutral
2022-02-03 Bestätigt Goldman Neutral
2022-01-13 Eingeleitet Redburn Buy
2022-01-12 Bestätigt BMO Capital Markets Outperform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-11-23 Hochstufung Societe Generale Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2020-11-10 Fortgesetzt Bernstein Outperform
2020-09-29 Eingeleitet Berenberg Hold
2020-06-23 Hochstufung Atlantic Equities Neutral → Overweight
2020-06-09 Hochstufung Wolfe Research Peer Perform → Outperform
2020-06-02 Hochstufung Argus Hold → Buy
2020-05-18 Fortgesetzt BofA/Merrill Neutral
2020-05-12 Hochstufung JP Morgan Neutral → Overweight
2020-05-11 Fortgesetzt Morgan Stanley Overweight
2020-04-20 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-26 Bestätigt Cowen Outperform
2019-09-26 Hochstufung Citigroup Neutral → Buy
2019-08-20 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-27 Hochstufung Wolfe Research Underperform → Peer Perform
2019-06-26 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-05-28 Eingeleitet Goldman Neutral
2019-04-29 Hochstufung BMO Capital Markets Underperform → Market Perform
Alle ansehen

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

pulisher
08:07 AM

Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative

08:07 AM
pulisher
01:45 AM

AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business

01:45 AM
pulisher
01:09 AM

AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters

01:09 AM
pulisher
10:47 AM

AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News

10:47 AM
pulisher
10:30 AM

Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily

10:30 AM
pulisher
08:46 AM

Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com

08:46 AM
pulisher
12:11 PM

What drives AbbVie Inc. stock priceFree Technical Analysis Support - PrintWeekIndia

12:11 PM
pulisher
12:03 PM

AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest

12:03 PM
pulisher
Jul 20, 2025

Is AbbVie Inc. a good long term investmentMassive stock growth - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

AbbVie Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year - The Motley Fool

Jul 19, 2025
pulisher
Jul 19, 2025

AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks

Jul 19, 2025
pulisher
Jul 18, 2025

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch

Jul 18, 2025
pulisher
Jul 18, 2025

Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox

Jul 18, 2025
pulisher
Jul 17, 2025

Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Venetoclax Study in Greece: A Closer Look at CLL Treatment Outcomes - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Real-World Study on Upadacitinib for Crohn’s Disease: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Real-World Study on OZURDEX: A Closer Look at Market Implications - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie’s Pediatric IBS-D Study: A Potential Game-Changer for Eluxadoline - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie Completes Phase 1 Trial of ALIA-1758: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie: Why I Set A $175 Buy Order (NYSE:ABBV) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times

Jul 17, 2025
pulisher
Jul 17, 2025

Glenmark Pharma will turn cash positive with AbbVie's licensing deal S P - theweek.in

Jul 17, 2025
pulisher
Jul 17, 2025

Immunology Market Growth in Future Scope 2025-2032 | AbbVie - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie's (NYSE:ABBV) Investors Will Be Pleased With Their Strong 138% Return Over the Last Five Years - 富途牛牛

Jul 17, 2025
pulisher
Jul 17, 2025

AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025

Finanzdaten der Abbvie Inc-Aktie (ABBV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$164.36
price up icon 0.40%
drug_manufacturers_general NVS
$114.14
price down icon 0.10%
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
$295.87
price up icon 0.38%
Kapitalisierung:     |  Volumen (24h):